Page last updated: 2024-11-03

procaterol and Obstructive Lung Diseases

procaterol has been researched along with Obstructive Lung Diseases in 2 studies

Procaterol: A long-acting beta-2-adrenergic receptor agonist.

Research Excerpts

ExcerptRelevanceReference
" The characteristics of the oral route are easy usage, precise dosage and assured effects."1.27Oral beta 2-selective adrenergic bronchodilators. ( Daniotti, S; Dottorini, M; Grassi, V; Schiassi, M; Tantucci, C, 1986)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Grassi, V1
Daniotti, S1
Schiassi, M1
Dottorini, M1
Tantucci, C1
Baronti, A1
Lelli, M1
Manini, G1
Verdiani, P1

Trials

1 trial available for procaterol and Obstructive Lung Diseases

ArticleYear
Procaterol metered aerosol in patients with chronic obstructive pulmonary disease.
    International journal of clinical pharmacology research, 1987, Volume: 7, Issue:5

    Topics: Adrenergic beta-Agonists; Aerosols; Aged; Bronchodilator Agents; Drug Tolerance; Ethanolamines; Fema

1987

Other Studies

1 other study available for procaterol and Obstructive Lung Diseases

ArticleYear
Oral beta 2-selective adrenergic bronchodilators.
    International journal of clinical pharmacology research, 1986, Volume: 6, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Agonists; Aged; Asthma; Bronchodilator Agents; Child; Clenbute

1986